Treatment of Lateral Epicondylosis by Using Allogeneic Adipose‐Derived Mesenchymal Stem Cells: A Pilot Study

Mesenchymal stem cell therapy is a novel regenerative approach for treating tendinopathy. Here, we evaluated the safety and efficacy of allogeneic adipose‐derived mesenchymal stem cells (allo‐ASC) in treating lateral epicondylosis (LE). Under ultrasound guidance, allo‐ASCs mixed with fibrin glue wer...

Full description

Saved in:
Bibliographic Details
Published inStem cells (Dayton, Ohio) Vol. 33; no. 10; pp. 2995 - 3005
Main Authors Lee, Sang Yoon, Kim, Won, Lim, Chaiyoung, Chung, Sun G.
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.10.2015
Subjects
Adipose tissue
Adipose Tissue - cytology
Adult
Allograft
Allografts
Female
Humans
Injection
Male
Mesenchymal Stem Cell Transplantation
Mesenchymal Stromal Cells - cytology
Middle Aged
Pain
Stem cells
Tendinopathy
Tendinopathy - pathology
Tendinopathy - therapy
Tennis elbow
Tennis Elbow - pathology
Tennis Elbow - therapy
Tendinopathy
Adipose tissue
Allograft
Mesenchymal stem cell transplantation
Tennis elbow
Online AccessGet full text

Cover

More Information
Summary:Mesenchymal stem cell therapy is a novel regenerative approach for treating tendinopathy. Here, we evaluated the safety and efficacy of allogeneic adipose‐derived mesenchymal stem cells (allo‐ASC) in treating lateral epicondylosis (LE). Under ultrasound guidance, allo‐ASCs mixed with fibrin glue were injected into the hypoechoic common extensor tendon lesions of 12 participants with chronic LE; 6 subjects each were administered 106 or 107 cells in 1 ml. Safety was evaluated at day 3 and weeks 2, 6, 12, 26, and 52 post‐injection. Efficacy was assessed by measuring patients’ visual analog scale (VAS) score for elbow pain, modified Mayo clinic performance index for the elbow, and by evaluating longitudinal and transverse ultrasound images of tendon defect areas after 6, 12, 26, and 52 weeks. No significant adverse effects of allo‐ASC injection were observed through 52 weeks of follow‐up. From baseline through 52 weeks of periodic follow‐up, VAS scores progressively decreased from 66.8 ± 14.5 mm to 14.8 ± 13.1 mm and elbow performance scores improved from 64.0 ± 13.5 to 90.6 ± 5.8. Tendon defects also significantly decreased through this period. Allo‐ASC therapy was thus safe and effective in improving elbow pain, performance, and structural defects for 52 weeks. This clinical study is the first to reveal therapeutic value of mesenchymal stem cell injection for treating chronic tendinopathy. Stem Cells 2015;33:2995–3005
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1066-5099
1549-4918
DOI:10.1002/stem.2110